News

NICE delays decision on drugs for macular degeneration

BMJ 2007; 335 doi: 10.1136/bmj.39307.507558.DB (Published 16 August 2007)
Cite this as: BMJ 2007;335:319.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Caroline White
  1. London

    The National Institute for Health and Clinical Excellence (NICE) has had to delay its final decision on two drugs for age related macular degeneration after mounting pressure from charities and healthcare professionals.

    NICE, which advises health authorities in England and Wales on the treatments to use on the NHS, issued preliminary guidance in June on the use of ranibizumab (marketed as Lucentis) and pegaptanib (Macugen) for the treatment of the disease. Both drugs are already available in Scotland.

    It argued that pegaptanib should not be used at all and that ranibizumab should be …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular